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Abstract: 
Objective: The aims of this study were to examine the cytotoxic and apoptotic effects of KL-21, a novel plant product 
(produced by naturin natural Products, İzmir, Turkey), on 232B4 chronic lymphocytic leukemia (CLL) cells and to determine 
the cytotoxic effects on healthy BEAS-2B human bronchial epithelial cells. 
Materials and Methods: The cytotoxic effect of KL-21 was determined by MTT cell proliferation assay. Changes in 
caspase-3 enzyme activity were measured using the caspase-3 colorimetric assay. Changes in mitochondrial membrane 
potential were determined using the JC-1 dye-based method. Annexin V-FITC/PI double staining was performed to measure 
the apoptotic cell population. Effects of KL-21 on cell cycle profiles of CLL cells were investigated by flow cytometry. 
Results: We detected time- and concentration-dependent increases in the cytotoxic effect of KL-21 on 232B4 CLL cells. 
However, we also showed that, especially at higher concentrations, KL-21 was less cytotoxic towards BEAS-2B healthy cells 
than towards CLL cells. Annexin-V/PI double staining results showed that the apoptotic cell population increased in 232B4 
cells. Increasing concentrations of KL-21 increased caspase-3 enzyme activity and induced loss of mitochondrial membrane 
potential. KL-21 administration resulted in small increases in the percentage of the cells in the G0/G1 phase while it decreased 
the S phase cell population up to 1 mg/mL. At the highest concentration, most of the cells accumulated in the G0/G1 phase. 
Conclusion: KL-21 has a growth-inhibitory effect on 232B4 CLL cells. KL-21 causes apoptosis and cell cycle arrest at G0/G1.
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Introduction
Chronic lymphocytic leukemia (CLL) is a monoclonal 
disorder characterized by an increase in the number of 
functionally deficient mature CD5+ B lymphocytes in the 
blood, bone marrow, lymph nodes, and spleen [1,2]. CLL is 
most commonly observed in Western countries and affects 
mainly older individuals [3,4]. The main purposes of CLL 
treatment are to reduce cancer progression and induce 
apoptosis while providing quality of life for patients. Treatment 
approaches for CLL include chemotherapy, radiotherapy, 
immunotherapy, and bone marrow transplantation (BMT) 
with high-dose chemotherapy [4,5]. Among these treatment 
options, purine analogs such as fludarabine and cladribine, 
alkylating agents like chlorambucil, and alkylating agent/
anthracycline combinations are frequently used [6]. 
Rituximab, a chimeric anti-CD20 monoclonal antibody, and 
alemtuzumab, a monoclonal antibody against the CD52 
antigen, have received attention in the treatment of CLL due 
to their increased specificity as compared to chemotherapy 
[7,8]. BMT has been reported to decrease mortality when it is 
applied early in the course of the disease [9]. However, BMT, 
especially allogeneic BMT, is not considered as an appropriate 
regimen for CLL patients since most CLL patients are older 
than 55 years [10,11]. Although all the methods used in 
the treatment of CLL are effective, none of the standard 
therapies are capable of completely eliminating CLL. On the 
other hand, these methods have distinct side effects in the 
treatment of CLL [5]. Moreover, CLL remains an incurable 
disease with conventional therapies due to development of 
relapse or refraction [12]. For these reasons, it is necessary to 
improve the treatments for relapsed or refractory CLL or to 
develop new therapeutic agents that are less toxic and more 
effective for the complete elimination of CLL cells. Use of 
plant-derived substances such as resveratrol and quercetin 
has been indicated in several studies for CLL treatment, either 
alone or in combination with other agents [13,14]. KL-21 is 
a novel agent of plant origin produced by Naturin Natural 
Products (İzmir, Turkey) for the treatment of CLL. Ethical 
committee approved this study. In the present study, we aimed 
to investigate the possible cytotoxic and apoptotic effects of 
KL-21 on 232B4 CLL cells.
Materials and Methods
Cell Lines and Culture Conditions and Chemicals 
Human 232B4 CLL cells were kindly provided by Prof. 
Dr. Ander Rosen from Linköping University, Sweden. Healthy 
human BEAS-2B epithelial cells were obtained from Assist. 
Prof. Dr. Ali Çağır from İzmir Institute of Technology and were 
used as a positive control. The cells were grown and maintained 
in RPMI-1640 medium containing 10% fetal bovine serum and 
1% penicillin-streptomycin at 37 °C in 5% CO2. A 10 mg/mL 
stock solution of KL-21 was prepared in DMSO and stored at 
-20 °C. The final concentration of DMSO did not exceed more 
than 0.1% in culture. KL-21 is a novel plant extract containing 
extracts from 21 plant species in different amounts. KL-21 is 
Özet:
Amaç: Bu çalışmanın amacı yeni bitkisel bir ürün olan KL-21’in [naturin doğal ürünler şirketi (İzmir, Türkiye) tarafından 
üretilen] 232B4 kronik lenfostik lösemi (KLL) hücreleri üzerindeki sitotoksik ve apoptotik etkilerinin araştırılmasıdır. Ayrıca, 
KL-21’in BEAS-2B sağlıklı insan bronşial epitelyum hücreleri üzerindeki sitotoksik etkisine de bakılmıştır.
Gereç ve Yöntemler: KL-21’in sitotoksik etkisine MTT hücre çoğalma testiyle bakılmıştır. Kaspaz-3 enzim aktivitesindeki 
ve mitokondri membran potansiyelindeki değişimlere sırasıyla kaspaz-3 kolorimetrik testi ve JC-1 boyasına dayalı bir yöntem 
kullanılarak bakılmıştır. Apoptotik hücre popülasyonunu belirlemek amacıyla Anneksin 5-FITC/PI ikili boyama yöntemi 
kullanılmıştır. KL-21’in KLL hücrelerinin hücre siklusu üzerindeki etkilerine akım sitometresi ile bakılmıştır.
Bulgular: KL-21’in KLL hücrelerinin çoğalması üzerine etkisi zamana ve doza bağımlı olarak artmıştır. Bununlar beraber, KL-
21’in özellikle yüksek konsantrasyonlarda KLL hücreleri ile karşılaştırıldığında BEAS-2B hücreleri üzerinde daha az sitotoksik etki 
gösterdiği saptanmıştır. Anneksin-5/PI ikili boyaması 232B4 hücrelerinde apoptotik hücre popülasyonunun arttığını göstermiştir. 
KL-21’in artan konsantrayonları kaspaz-3 enzim aktivitesini arttırmış ve mitokondri membran potansiyelindeki kayıpları 
indüklemiştir. KL-21 1 mg/ml konsantrasyonuna kadar G0/G1 fazındaki hücrelerin yüzdesinde küçük artışlara ve S fazındaki 
hücre popülasyonunda ise azalmalara neden olmaktadır. En yüksek konsantrasyonda ise hücrelerin büyük bir çoğunluğu G0/G1 
fazında birikmiştir.
Sonuç: Elde edilen sonuçlar, KL-21’in 232B4 KLL hücreleri üzerinde büyümeyi inhibe edici bir etkisi olduğunu göstermiştir. 
Ayrıca, K-21 apoptozu indüklemekte ve G0/G1 fazında hücre siklusunun tutulumuna neden olmaktadır.
Anahtar Sözcükler: Apoptoz, Hücre siklusu tutulması, Kronik lenfositik lösemi, KL-21
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a mixture of Achillea millefolium (8.47%), Juniperus communis 
(7.62%), Thymus vulgaris (6.78%), Peganum harmala (6.78%), 
Curcuma longa (6.78%), Silybum marianum (6.78%), Urtica 
dioica (6.77%), Equisetum arvense (5.93%), Lavandula stoechas 
(5.93%), Zingiber officinale (5.08%), Fumaria officinalis 
(4.24%), Taraxacum officinale (4.24%), Rosmarinus officinalis 
(4.23%), Nigella sativa (4.23%), Cichorium endivia (3.39%), 
Viscum album (2.54%), Solidago virgaurea (2.54%), Hypericum 
perforatum (2.54%), Acorus calamus (1.69%), Valeriana 
officinalis (1.69%), and Melissa officinalis (1.69%).
Measurement of Cell Growth by MTT Assay 
Antiproliferative effects of KL-21 were determined by the 
MTT cell proliferation assay as described. The IC50 value (the 
drug concentration that inhibits cell growth by 50%) of KL-21 
was calculated according to cell proliferation plots [15].
Annexin-V/PI Double Staining 
We determined the translocation of phosphatidylserine 
from the inner membrane to the outer cell membrane in order 
to examine the apoptotic effects of KL-21 on CLL cells. Initially, 
1x106 cells were treated with increasing concentrations of KL-
21 (0.001 to 1 mg/mL) for 48 h. After incubation, the cells 
were washed twice with cold phosphate buffered saline (PBS) 
and then homogenized with 1 mL of 1X binding buffer, and 
then 100 µL of this solution was added into glass tubes. Next, 
5 µL of FITC annexin V and 5 µL of propidium iodide (PI) 
were added to the cell solutions. These samples were vortexed 
gently and then incubated for 15 min at room temperature in 
the dark. Afterwards, 400 µL of 1X binding buffer was added 
to each tube, and samples were analyzed by flow cytometry 
(BD FACSCanto Flow Cytometer, Belgium) within 1 h.
Analysis of the Changes in Mitochondrial Membrane 
Potential 
We examined the loss of mitochondrial membrane potential 
(MMP) in response to KL-21 in 232B4 cells with the JC-1 
Mitochondrial Membrane Potential Detection Kit (Cayman 
Chemicals, USA). Briefly, the cells (1x106 cells/2 mL), induced 
to undergo apoptosis, were collected by centrifugation at 
180 x g for 10 min. Supernatants were removed and pellets 
were homogenized with 300 µL of medium, and then 30 µL of 
JC-1 dye was added to the cells and the cells were incubated 
at 37 °C in 5% CO2 for 30 min. They were centrifuged at 400 
x g for 5 min, supernatants were removed, and 200 µL of 
assay buffer was added to the pellets and vortexed. This step 
was then repeated. Afterwards, all pellets were homogenized 
with 320 µL of assay buffer and 100 µL from each sample 
was added to a 96-well plate as triplicates. In healthy cells, 
the aggregate red form has absorption/emission maxima of 
560/595 nm, whereas in apoptotic cells, the monomeric green 
form has absorption/emission maxima of 485/535 nm. The 
plate was read in these wavelengths with a fluorescence ELISA 
reader (Thermo Varioskan Spectrum, Finland). The ratio of 
fluorescent intensity of JC-1 monomers to fluorescent intensity 
of JC-1 aggregates was calculated for each concentration as 
well as the untreated control sample. Relative changes in 
cytoplasmic/mitochondrial JC-1 were then determined [16].
Analysis of Caspase-3 Activity 
Changes in caspase-3 activity of the cells were examined 
with a caspase-3 colorimetric assay kit (BioVision Research 
Products, USA). In short, the cells (1x106 cells/2 mL/well), 
induced to undergo apoptosis by KL-21, were collected by 
centrifugation at 180 x g for 10 min. The cells were lysed by 
adding 50 µL of chilled Cell Lysis Buffer and incubated on 
ice for 10 min before centrifugation at 10,000 x g for 1 min. 
Supernatants were transferred to new Eppendorf tubes, and 
the reaction mixture was prepared in 96-well plates by adding 
50 µL of 2X reaction buffer (containing 10 mM DTT), 50 µL of 
sample, and 5 µL of DEVD-pNA substrate and was incubated 
for 2 h at 37 °C in a CO2 incubator. At the end of this period, 
the plate was read under 405 nm wavelengths with an ELISA 
reader. The absorbance values were normalized to protein 
concentrations determined by the Bradford assay. 
Cell Cycle Analysis 
This technique is based on the determination of amounts 
of dsDNA by using PI and flow cytometry. Briefly, 1x106 
cells/2 mL were treated with increasing concentrations of KL-
21 for 48 h. After the incubation period, cells were collected 
by centrifugation at 260 x g for 10 min. Supernatants were 
removed and pellets were homogenized with 1 mL of cold 
PBS, and then the samples were put on ice. Afterwards, while 
the cells were slightly vortexed, 4 mL of cold ethanol was 
added to these cells, and then the mixture was put on ice. 
Cells fixed by this method were incubated overnight at -20 °C 
for analysis. The next day, the cells were centrifuged at 260 x g 
for 10 min, and supernatants were completely removed from 
the pellets. Pellets were homogenized with 1 mL of cold PBS 
and were centrifuged again at 260 x g for 10 min. Afterwards, 
cell pellets were homogenized with 1 mL of PBS containing 
0.1% Triton X-100; 100 µL of RNase A (200 µg/mL) was then 
added to these cells and the mixture was incubated at 37 °C 
for 30 min. After this incubation period, 100 µL of PI (1 mg/
mL) was added to the cells. These cells were incubated at 
room temperature for 15 min and were then analyzed by flow 
cytometry.
Statistical Analysis 
Statistical significance was determined via GraphPad 
Prism 6.0 software using 1-way analysis of variance 
(ANOVA) for MTT analyses and 2-way ANOVA for annexin 
V, MMP, caspase-3 activity and cell cycle analyses. P<0.05 was 
considered to be significant. MTT, annexin V, MMP, caspase-3, 
and cell cycle analysis results were shown as the means of 3 
independent experiments (N).
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Results
Cytotoxic Effects of KL-21 on 232B4 CLL and BEAS-2B 
Epithelial Cells 
There were decreases in the viability/proliferation of 
232B4 CLL cells in a dose- and time-dependent manner 
(Figure 1A), while KL-21 had very little or no effect on the 
viability of BEAS-2B healthy cells at up to 0.1 mg/mL (Figure 
1B). Although KL-21 was cytotoxic toward healthy control 
cells at higher concentrations (0.5 and 1 mg/mL), more than 
20% of cells were alive at indicated time points. IC50 values of 
KL-21 for 232B4 cells at 24, 48, and 72 h were calculated from 
cell proliferation plots and were found to be 0.2, 0.1, and 0.08 
mg/mL, respectively. On the other hand, IC50 values of KL-21 
for BEAS-2B cells were found to remain at about 0.4 mg/mL 
at each time point. These findings indicated that CLL cells are 
more susceptible than BEAS-2B cells to the growth inhibitory 
effects of KL-21.
KL-21 Induced Apoptosis in a Dose-Dependent Manner 
in 232B4 Cells 
The percentage of the apoptotic cell population (late 
apoptotic plus early apoptotic) of 232B4 cells was determined 
by flow cytometry. There were 1.16-, 1.23-, 1.28-, 1.77-, and 
3.23-fold increases in percentage of apoptotic cells treated 
with 0.001, 0.01, 0.05, 0.1, and 1 mg/mL KL-21, respectively, 
when compared to untreated controls, as shown in Figures 2A 
and 2B. The data showed that KL-21 triggers apoptosis in a 
dose-dependent manner.
KL-21 Induced Loss of Mitochondrial Membrane 
Potential in 232B4 Cells 
There were 1.31-, 1.45-, 3.6-, 4.12-, and 14.4-fold 
increases in loss of MMP in 232B4 cells treated with 0.001, 
0.01, 0.05, 0.1, and 1 mg/mL KL-21, respectively, as compared 
to untreated control cells (Figure 3).
KL-21 Increased Caspase-3 Activity in 232B4 CLL Cells 
There were 1.02-, 1.03-, 1.23-, 1.52-, and 2.12-fold 
increases in caspase-3 enzyme activity in response to 0.001, 
0.01, 0.05, 0.1, and 1 mg/mL KL-21, respectively, as compared 
to untreated controls (Figure 4).
KL-21 Induced G0/G1 Arrest in 232B4 Cells 
In order to determine the possible mechanism of 
antiproliferative activity of KL-21, cell cycle progression of 
Figure 1. Cytotoxic effects of KL-21 on human 232B4 CLL 
cells (A) and BEAS-2B healthy cells (B) with statistical 
analysis. The IC50 value of KL-21 was calculated from cell 
proliferation plots. The results are the means of 3 independent 
experiments. The error bars represent the standard deviations. 
Statistical significance was determined using 1-way analysis of 
variance and p<0.05 was considered to be significant. 
A
B
Figure 2. Evaluation of apoptosis in 232B4 cells induced 
by KL-21. The percentage of cells undergoing early and late 
apoptosis in a dose-dependent manner as compared to the 
control and flow cytometry analysis via annexin V-FITC/PI 
staining is shown (A and B). Cells in the lower right quadrant 
are annexin-positive/PI-negative early apoptotic cells. The 
cells in the upper right quadrant are annexin-positive/PI-
positive late apoptotic cells. The percentage of cells annexin 
V-positive, PI-positive, or double positive for both annexin V 
and PI is indicated. The results are the means of 3 independent 
experiments. 
A
B
B
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232B4 cells was examined by flow cytometry in the presence 
of DNase-free RNase and PI dye. As summarized in Figures 
5A and 5B, treatment of 232B4 cells with KL-21 resulted in 
small increases in the percentage of cells in the G0/G1 phase 
at 0.001 to 0.1 mg/mL, but there was a significant increase in 
response to 1 mg/mL KL-21.
Discussion
CLL is an adult leukemia characterized by accumulation 
of malignant B cells in several parts of the body. Despite 
the presence of many therapeutic regimens, CLL is still an 
incurable disorder [2]. CLL can be effectively treated with 
various agents; however, these strategies have their own side 
effects and some patients have limited therapeutic options 
[5,17]. Therefore, there is a need to discover novel drugs or 
agents for CLL treatment. 
We conducted this study to examine the cytotoxic and 
apoptotic effects of KL-21, a novel plant-derived product, on 
232B4 CLL cells. KL-21 decreased proliferation of 232B4 CLL 
cells in a dose- and time-dependent manner. Moreover, we 
found that KL-21 did not have an antiproliferative effect on 
BEAS-2B cells at concentrations between 0.001 and 0.1 mg/
mL. Although KL-21 was cytotoxic towards healthy cells, CLL 
cells were more susceptible to the cytotoxic effects of 0.5 and 
1 mg/mL KL-21. On the other hand, annexin-V/PI double 
staining showed dose-dependent increases in the apoptotic cell 
population in response to KL-21 when compared to untreated 
controls. To elucidate the molecular mechanism of KL-21-
induced apoptosis in CLL cells, we first checked the effect of 
KL-21 on MMP. The results revealed that KL-21 caused loss of 
MMP in a dose-dependent manner. In the literature, it is very 
well established that alterations in the structure and function 
of mitochondria play an important role in caspase-dependent 
apoptosis. Caspase-3, the executioner caspase, functions 
in the last step of caspase-mediated apoptosis. Therefore, 
we next checked the activation of caspase-3 enzyme in KL-
21-treated 232B4 cells. Our data demonstrated that KL-21 
increased caspase-3 activity in a dose-dependent manner 
when compared to untreated controls. Taken together, we can 
conclude that KL-21 induces apoptosis in 232B4 cells through 
the loss of MMP and caspase-3 activation. We also investigated 
Figure 4. Changes in caspase-3 enzyme activity in response 
to KL-21. The results are the means of 3 independent 
experiments. The error bars represent the standard deviations. 
Statistical significance was determined using 2-way analysis of 
variance and p<0.05 was considered to be significant.
Figure 3. Percent changes in cytoplasmic/mitochondrial JC-1 
in CLL cells treated with increasing concentrations of KL-
21. The results are the means of 3 independent experiments. 
The error bars represent the standard deviations. Statistical 
significance was determined using 2-way analysis of variance 
and p<0.05 was considered to be significant.
Figure 5. Effect of KL-21 on cell cycle progression. The 
percentage of cells in cell cycle phases are shown in the graph 
(A) and in quadrants (B). The results represent 3 independent 
experiments. Statistical significance was determined using 
2-way analysis of variance and p<0.05 was considered to be 
significant.
B
A
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Table 1. Botanical data of plant species included in KL-21.
Plant name Traditional and/or Medicinal Use Active Constituents of the Plant References
Achillea millefolium Breast and liver cancer, hardness of uterus, warts Flavonoids, sesquiterpenoids [21]
Urtica dioica Diabetes, rheumatism, eczema, anemia, hair loss, 
prostatic hyperplasia
Steroids, terpenoids, flavonol 
glycosides
[22]
Equisetum arvense Bleeding from the intestine or hemorrhoids, 
growth-inhibitory effects on melanoma
Alkaloids, flavonoids, phenolics, 
tannin
[23,24]
Thymus vulgaris Respiratory and gastrointestinal diseases Mono- and diterpenoids, flavonoids, 
biphenyl compounds
[25]
Viscum album Used as complementary medicine for solid 
tumors
Mistletoe lectins, viscotoxins, 
flavonoids, triterpene acids
[26,27]
Acorus calamus Epilepsy, chronic diarrhea, dysentery, abdominal 
tumors
Sesquiterpenes and their alcohols, 
flavonoids, choline
[28]
Solidago virgaurea Urinary tract, nephrolithiasis, prostate cancer Saponins, α-tocopherol quinone, 
trans-phytol
[29,30]
Silybum marianum Diabetes mellitus,
hepatic disorders 
Silibinin, silymarin [31,32]
Curcuma longa Cough, diabetic wounds, hepatic disorders, 
rheumatism, sinusitis, anticarcinogen
Curcumin [polyphenol], an 
essential oil
[33]
Rosmarinus officinalis  Renal colic, dysmenorrhea, respiratory disorders  Rosmarinic acid, caffeic 
acid, rosmanol, different diterpenes
[34]
Lavandula stoechas Colic and chest affections, nervous headache, 
biliousness, wound healing
Essential oils [35]
Fumaria officinalis Hepatobiliary diseases Phenolics, alkaloids [36,37]
Taraxacum officinale Breast, uterine, lung tumors; hepatitis, digestive 
diseases
Luteolin, luteolin-7-glucoside [38,39]
Cichorium endivia Liver diseases Kaempferol, kaempferol-
3-O-β-D-glucoside, sesquiterpenes
[40]
Zingiber officinale Arthritis, migraine, diabetes, nausea Gingerols, sesquiterpenes [41]
Peganum harmala Skin, subcutaneous tumors Alkaloids [harmine, harmaline, 
harman]
[42,43]
Juniperus communis Dyspepsia, bladder and kidney diseases Terpinen-4-ol, sesquiterpenes [44]
Nigella sativa Asthma, diarrhea, dyslipidemia Thymoquinone, alkaloids, saponin  [45]
Hypericum perfora-
tum
Skin wounds, eczema, burns, depression Hypericins, hyperforins, flavonoids [46]
Valeriana officinalis Insomnia Valepotriates, monoterpenes, sesqui-
terpenes
 [47]
Melissa officinalis Used as a mild sedative, spasmolytic,  
antibacterial agent
 Eugenol, tannin, terpenes  [48]
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the cytostatic property of KL-21 on CLL cells and observed 
that the treatment of CLL cells with KL-21 resulted in G0/
G1 phase arrest of cell cycle progression, especially at high 
concentrations. Cells may either undergo repair or enter the 
apoptotic pathway following the G1 phase of the cell cycle 
to eliminate mutated or neoplastic cells. In the present study, 
we observed that CLL cells undergo significant apoptosis in 
response to KL-21 treatment. Therefore, it can be concluded 
that, in addition to the mitochondrial pathway of apoptosis, 
G1 phase arrest may be another mechanism of apoptosis in 
these cells, especially at high concentrations of KL-21.
By our group and some other groups it was reported that 
many plant-derived products have been shown to induce 
apoptosis in CLL cells. Honokiol, a plant product, triggers 
apoptosis in CLL cells via activation of caspase-3, -8, and -9, 
and apoptosis was further evaluated by annexin-V/PI double 
staining [18]. Gokbulut et al. showed that resveratrol and 
quercetin might block CLL growth by inducing apoptosis and 
cell cycle arrest [19]. The growth inhibition and induction 
of apoptosis in CLL cells treated with flavopiridol, which is 
isolated from the Indian plant Dysoxylum binectariferum, has 
been related to the downregulation of Bcl-2 [20].
KL-21 is a novel plant extract that is the herbal 
combination of 21 plant species at different percentages as 
described above. These plant species have been widely used 
in traditional medicine all over the world for the treatment 
of different diseases and some types of cancer. Most of them 
possess antiinflammatory, antiviral, antibacterial, antioxidant, 
and anticarcinogenic properties. Detailed information about 
the ingredients of KL-21 and their use in medicine is given 
in Table 1. As summarized in Table 1, terpenoids, flavonoids, 
and their derivatives are the main effective components of 
KL-21, similar to several plant-derived medicinal extracts. 
The main mechanisms of flavonoids include induction of 
apoptosis, cell cycle arrest, and inhibition of angiogenesis 
[49]. Terpenoids possess anticarcinogenic activities and their 
mechanisms of action include inhibition of NF-κB signaling, 
induction of apoptosis, and cell cycle arrest [50,51]. Other 
ingredients are generally plant-specific and their effects have 
been explained in several studies. For instance, the antitumor 
activity of hypericin from Hypericum perforatum has been 
shown to be related to the release of cytochrome c, activation 
of caspase-3, and partial inhibition of protein kinase C [52,53]. 
In conclusion, we demonstrated that KL-21 has growth-
inhibitory effects on 232B4 CLL cells. KL-21 causes apoptosis 
and cell cycle arrest at G0/G1. While the complete mechanism 
of apoptosis needs to be elucidated, we have shown that KL-21 
induced apoptosis by the mitochondrial/caspase-3-dependent 
pathway and the inhibition of cell cycle progression through 
the G0/G1 phase. Therefore, given its active plant constituents, 
the results of this study suggest that KL-21 could be a novel 
promising natural agent for the treatment of CLL. 
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